Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial - Feagan, Brian G; Danese, Silvio; Loftus, Edward V; Vermeire, Séverine; Schreiber, Stefan; Ritter, Timothy; Fogel, Ronald; Mehta, Rajiv; Nijhawan, Sandeep; Kempiński, Radosław; Filip, Rafał; Hospodarskyy, Ihor; et al. (The Lancet (British edition), 2021)
Keywords: Adult; Adverse events; Analysis; Antagonists; Arthritis; Care and treatment; Clinical trials; Colitis, Ulcerative; Colitis, Ulcerative - drug therapy; Corticoids; Corticosteroids; Crohn's disease; Dosage; Dose-Response Relationship, Drug; Double-Blind Method; Double-blind studies; Endoscopy; Enzyme inhibitors; Female; Humans; Immunosuppressive agents; Inflammatory bowel disease; Intolerance; Janus kinase; Janus Kinase Inhibitors; Kinases; Life Sciences; Maintenance; Male; Monoclonal antibodies; Pathogenesis; Patients; Pharmacokinetics; Placebos; Pyridines; Pyridines - administration & dosage; Remission; Remission Induction; Safety; Treatment Outcome; Triazoles; Triazoles - administration & dosage; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumors; Ulcerative colitis; United States--US; South Korea; Germany